Struvite Urolithiasis

Struvite urolithiasis is a common urinary tract disorder characterized by the formation of magnesium ammonium phosphate hexahydrate (MgNH4PO4·6H2O) calculi within the urinary tract, primarily affecting the bladder and urethra. In dogs, struvite stones are most frequently associated with urinary tract infections (UTIs) caused by urease-producing bacteria, whereas in cats, struvite stones often form in sterile urine, typically in the context of concentrated urine and dietary factors. The disease encompasses a spectrum from asymptomatic crystalluria to life-threatening urethral obstruction, with significant morbidity if not promptly diagnosed and managed. Struvite urolithiasis is a major cause of lower urinary tract signs (LUTS) in both species, and its management requires a comprehensive approach addressing infection, diet, and metabolic risk factors.

The primary etiologic factor in canine struvite urolithiasis is infection with urease-producing bacteria, most commonly Staphylococcus pseudintermedius, but also Proteus mirabilis, Klebsiella pneumoniae, and occasionally Corynebacterium renale. Urease hydrolyzes urea to ammonia and carbon dioxide, increasing urine pH (typically >7.0) and promoting the crystallization of magnesium, ammonium, and phosphate ions. In cats, sterile struvite formation is more common, often associated with concentrated urine (urine specific gravity >1.040), acidic to neutral pH (6.0-7.0), and dietary factors such as high magnesium, phosphorus, and protein content, although modern diets are formulated to reduce this risk. Other contributing factors include urinary stasis, reduced water intake, and genetic predispositions. In rare cases, metabolic disorders such as hyperadrenocorticism or primary hyperparathyroidism may predispose to struvite formation by altering mineral metabolism.

Struvite urolithiasis is one of the most prevalent urolith types in dogs and cats. In dogs, it accounts for approximately 50-60% of all uroliths, with a higher incidence in females due to increased susceptibility to UTIs. Breeds such as Miniature Schnauzers, Bichon Frises, and Shih Tzus are overrepresented. In cats, struvite uroliths are the most common type, comprising 40-50% of feline uroliths, with a peak incidence in young to middle-aged adults (2-6 years). No strong breed predilection exists, but Persian and Himalayan cats may be at higher risk. The condition is more common in indoor cats with low water intake and in animals fed dry diets. Geographic variation exists, with higher incidence in regions with hard water, though this is not a proven risk factor. Seasonality is not significant, but UTIs may be more common in warmer months.

The pathophysiology of struvite urolithiasis involves supersaturation of urine with magnesium, ammonium, and phosphate ions, leading to crystal nucleation, aggregation, and stone growth. In infection-induced struvite, urease-producing bacteria colonize the urinary tract, hydrolyzing urea to ammonia, which raises urine pH and increases the concentration of ammonium ions. The alkaline environment reduces the solubility of struvite, promoting crystallization. Bacterial biofilms on the urothelium further enhance stone formation. In sterile struvite, high dietary intake of magnesium and phosphorus, combined with low urine volume, leads to supersaturation. Urine pH plays a critical role: struvite solubility is lowest at pH >7.0, but in cats, sterile struvite can form at pH 6.0-6.5 if urine is highly concentrated. Once formed, stones can cause mechanical irritation to the urothelium, leading to hematuria, dysuria, and inflammation. Urethral obstruction can occur, especially in male cats, leading to post-renal azotemia, hyperkalemia, and potentially fatal bladder rupture.

Predisposing factors for struvite urolithiasis include: (1) Urinary tract infections with urease-producing bacteria, particularly in dogs; (2) Female sex in dogs due to shorter, wider urethra facilitating ascending infections; (3) Concentrated urine from low water intake, especially in cats; (4) Dietary factors: high magnesium, phosphorus, and protein content, and dry food diets; (5) Urinary stasis from infrequent voiding, obesity, or neurologic dysfunction; (6) Genetic predisposition in certain breeds (e.g., Miniature Schnauzers); (7) Metabolic disorders such as hyperadrenocorticism or hyperparathyroidism that alter calcium and phosphorus metabolism; (8) Medications that affect urine pH or mineral excretion, such as furosemide or glucocorticoids; (9) Inadequate dietary moisture and low urine output; (10) In cats, stress and environmental factors that reduce water intake.

Clinical signs of struvite urolithiasis vary depending on the location, size, and number of stones, and the presence of obstruction. Common signs include: (1) Pollakiuria (increased frequency of urination); (2) Dysuria (difficulty or pain on urination); (3) Hematuria (blood in urine); (4) Stranguria (straining to urinate); (5) Periuria (urinating outside the litter box); (6) In male cats, urethral obstruction may present as anuria, vocalization, lethargy, vomiting, and collapse; (7) In dogs, signs may be subtle, with chronic UTIs leading to recurrent urinary tract infections. Physical examination may reveal a distended, painful bladder, and in cases of obstruction, a large, turgid bladder on palpation. Systemic signs such as fever, depression, and anorexia may occur with pyelonephritis or urosepsis. In chronic cases, weight loss and poor coat condition may be noted.

Differential diagnoses for struvite urolithiasis include: (1) Other urolith types: calcium oxalate, urate, cystine, and calcium phosphate stones, which require different management; (2) Urinary tract infection (bacterial cystitis) without urolithiasis; (3) Feline idiopathic cystitis (FIC), especially in cats with LUTS; (4) Neoplasia of the urinary bladder (e.g., transitional cell carcinoma); (5) Polyps or granulomatous lesions; (6) Urethral plugs (matrix-crystalline plugs) in cats; (7) Trauma to the urinary tract; (8) Anatomic abnormalities such as ectopic ureters or urethral strictures; (9) Neurologic disorders affecting micturition. Key distinguishing features include imaging findings (radiopaque vs. radiolucent stones), urinalysis (crystalluria, pH, infection), and culture results. For example, calcium oxalate stones are radiopaque and typically form in acidic urine, whereas struvite stones are often radiopaque but may be less dense; urate stones are radiolucent.

The diagnostic algorithm for struvite urolithiasis begins with a thorough history and physical examination, including abdominal palpation. Initial diagnostic tests include: (1) Complete blood count (CBC) and serum biochemistry to assess renal function and electrolyte status; (2) Urinalysis with urine specific gravity, pH, dipstick, and microscopic sediment examination for crystals, red blood cells, white blood cells, and bacteria; (3) Urine culture and sensitivity to identify bacterial infection and guide antimicrobial therapy; (4) Abdominal radiography to detect radiopaque stones (struvite is usually radiopaque); (5) Abdominal ultrasonography to identify stones, assess bladder wall thickness, and detect masses or other abnormalities; (6) If stones are not visible on radiographs, contrast studies (double-contrast cystography) or computed tomography (CT) may be needed. In cases of urethral obstruction, emergency stabilization is required before imaging. Definitive diagnosis is based on stone analysis (e.g., crystallography) after removal or dissolution. For cats with sterile struvite, dietary history and urine pH are important.

Laboratory findings in struvite urolithiasis include: (1) Hematology: may be normal, but leukocytosis with left shift may indicate infection or inflammation; (2) Serum biochemistry: may show azotemia (elevated BUN and creatinine) if obstruction or pyelonephritis is present; hyperkalemia and metabolic acidosis may occur with urethral obstruction; (3) Urinalysis: urine specific gravity is often high (>1.040) in cats; urine pH is typically alkaline (>7.0) in infection-induced struvite, but may be neutral in sterile struvite; hematuria, pyuria, and proteinuria are common; struvite crystals (coffin-lid shaped) may be seen in sediment, but their absence does not rule out urolithiasis; (4) Urine culture: positive for urease-producing bacteria in infection-induced cases; (5) Blood gas analysis: may reveal metabolic acidosis in obstructed patients; (6) Biomarkers: SDMA may be elevated in cases of renal impairment; NT-proBNP may be elevated in cardiac disease, but not specific; (7) In cats, serum magnesium and phosphorus levels may be elevated in some cases, but are not routinely measured.

Imaging findings in struvite urolithiasis: (1) Abdominal radiography: struvite stones are typically radiopaque, appearing as round or faceted mineral opacities in the bladder or urethra. They may be single or multiple, and vary in size. Radiography can also detect urethral calculi in male dogs and cats. (2) Ultrasonography: stones appear as hyperechoic foci with distal acoustic shadowing. Ultrasound can detect stones as small as 1-2 mm, assess bladder wall thickness (which may be thickened due to inflammation), and identify concurrent masses or polyps. (3) Contrast cystography: double-contrast cystography can outline radiolucent stones or filling defects. (4) Computed tomography (CT): CT is more sensitive than radiography for detecting small or radiolucent stones and can provide detailed 3D reconstruction for surgical planning. (5) In cases of urethral obstruction, retrograde urethrography may be performed to identify the location and number of stones.

Cytology and histopathology are not typically required for diagnosis of struvite urolithiasis, but may be performed in certain situations. (1) Fine needle aspiration (FNA) of bladder masses or thickened bladder wall may be performed to rule out neoplasia; cytology may show inflammatory cells (neutrophils, macrophages) and bacteria. (2) Histopathology of bladder tissue (biopsy) may be indicated if there is a suspicion of neoplasia or chronic cystitis; findings may include chronic inflammation, fibrosis, and epithelial hyperplasia. (3) Stone analysis (crystallography) is the gold standard for confirming struvite composition; it can be performed on voided stones or those removed surgically. (4) In cases of urethral plugs, microscopic examination may reveal struvite crystals embedded in a matrix of mucoprotein and cellular debris.

Treatment of struvite urolithiasis depends on the presence of infection, obstruction, and the size/location of stones. (1) Emergency stabilization: For urethral obstruction, immediate decompression via cystocentesis or urethral catheterization is required, along with fluid therapy to correct dehydration, electrolyte imbalances (especially hyperkalemia), and acidosis. (2) Medical dissolution: For infection-induced struvite in dogs, dissolution is possible with a calculolytic diet (e.g., Hill's s/d, Royal Canin Urinary S/O) and appropriate antimicrobial therapy based on culture and sensitivity. The diet is low in protein, magnesium, and phosphorus, and promotes acidic urine (pH <6.5). Dissolution typically takes 2-3 months. In cats, sterile struvite can be dissolved with a calculolytic diet alone, usually within 2-4 weeks. (3) Surgical intervention: Surgery (cystotomy) is indicated if stones are too large for dissolution, if there is a concurrent condition requiring surgery, or if medical dissolution fails. Urethral stones may require urethrotomy or urethrostomy. (4) Supportive care: Increase water intake (canned food, water fountains), encourage frequent urination, and manage pain with analgesics (e.g., buprenorphine, NSAIDs if no contraindications). (5) Antimicrobial therapy: For infection-induced struvite, antibiotics should be continued for at least 2-4 weeks after dissolution or surgery, and urine culture should be repeated to confirm clearance. (6) In cats with recurrent sterile struvite, long-term management includes a urinary health diet, increased water intake, and stress reduction.

The prognosis for struvite urolithiasis is generally good with appropriate treatment. For uncomplicated cases, medical dissolution is successful in 80-90% of dogs and cats. Recurrence rates are low if underlying causes (e.g., UTI, diet) are addressed. However, complications such as urethral obstruction can be life-threatening, with mortality rates up to 20-30% if not treated promptly. Chronic cases may lead to bladder wall fibrosis, recurrent UTIs, and in severe cases, renal damage. Negative prognostic indicators include delayed presentation, severe azotemia, hyperkalemia, and concurrent pyelonephritis. With surgical removal, the prognosis is excellent, but recurrence is possible if predisposing factors persist. Long-term follow-up is essential to monitor for recurrence.

Follow-up for struvite urolithiasis includes: (1) Recheck urinalysis and urine culture 2-4 weeks after initiation of treatment to assess response and adjust antimicrobial therapy; (2) Repeat imaging (radiography or ultrasound) every 2-4 weeks during medical dissolution to monitor stone size; (3) After dissolution or surgery, recheck urine pH and sediment every 3-6 months for the first year, then annually; (4) In dogs with recurrent UTIs, periodic urine cultures are recommended; (5) For cats on calculolytic diets, monitor body weight and renal function (BUN, creatinine, SDMA) every 6-12 months; (6) Adjust diet and water intake as needed to maintain urine pH in the target range (6.0-6.5 for cats, 6.5-7.0 for dogs on maintenance diets); (7) In cases of urethral obstruction, monitor for recurrence of obstruction and consider prophylactic urethrostomy in cats with recurrent obstructions.

Pearls: (1) Always perform urine culture in dogs with struvite urolithiasis, as infection is the primary cause; (2) In cats, sterile struvite is common, so avoid unnecessary antibiotics; (3) Medical dissolution is highly effective for struvite, but requires strict dietary compliance; (4) Urethral obstruction is an emergency; decompress the bladder immediately to prevent bladder rupture and hyperkalemia; (5) Use a urinary catheter with care to avoid trauma; (6) After dissolution, switch to a maintenance diet to prevent recurrence. Pitfalls: (1) Assuming all struvite stones are infection-induced; (2) Failing to culture urine before starting antibiotics; (3) Using a calculolytic diet in pregnant animals or growing puppies/kittens; (4) Not addressing underlying causes such as urinary stasis or obesity; (5) Discontinuing antibiotics too early, leading to persistent infection and stone recurrence; (6) Overlooking concurrent conditions like hyperadrenocorticism or chronic kidney disease.

Drug protocols for struvite urolithiasis are primarily focused on antimicrobial therapy and supportive care. (1) Antimicrobials: For infection-induced struvite, choose antibiotics based on culture and sensitivity. Common choices include: Amoxicillin-clavulanate (Clavamox) at 12.5-25 mg/kg PO q8-12h; Cephalexin at 22-30 mg/kg PO q8-12h; Enrofloxacin (Baytril) at 5-20 mg/kg PO q24h (use with caution in cats due to retinal toxicity); Trimethoprim-sulfamethoxazole at 15-30 mg/kg PO q12h. Duration: at least 2-4 weeks, and continue for 2-4 weeks after stone dissolution or surgery. (2) Analgesics: Buprenorphine at 0.01-0.02 mg/kg IV/IM/SC q8-12h for pain; NSAIDs (e.g., meloxicam at 0.1 mg/kg PO q24h) may be used in dogs if no contraindications (renal disease, dehydration). (3) Urinary acidifiers: In dogs, ammonium chloride or methionine may be used to acidify urine, but are rarely needed with calculolytic diets. (4) For urethral obstruction, treat hyperkalemia with insulin-dextrose (0.1 U/kg regular insulin IV with 2 g dextrose per unit), calcium gluconate (0.5-1.0 mL/kg of 10% solution IV over 10-20 min), and sodium bicarbonate (1-2 mEq/kg IV) if severe acidosis. (5) Fluid therapy: Isotonic crystalloids (e.g., Lactated Ringer's) at maintenance (60-100 mL/kg/day) or higher for dehydration. (6) In cats with recurrent sterile struvite, consider a urinary health diet and increase water intake; no specific drugs are indicated.

Evidence-based literature supports the following: (1) A study by Osborne et al. (1999) demonstrated that medical dissolution of infection-induced struvite uroliths in dogs is successful in 90% of cases when using a calculolytic diet and appropriate antibiotics. (2) In cats, a study by Lulich et al. (2001) showed that sterile struvite uroliths can be dissolved with a calculolytic diet alone in 80-90% of cases within 2-4 weeks. (3) ACVIM consensus statements on urolithiasis (2016) recommend urine culture for all dogs with struvite uroliths, and emphasize the importance of dietary management. (4) A meta-analysis by Houston et al. (2017) found that increasing water intake and feeding canned food significantly reduces the risk of struvite formation in cats. (5) Studies on urethral obstruction in cats (e.g., Gerber et al., 2008) highlight the importance of early decompression and fluid therapy to reduce mortality. (6) Current guidelines from IRIS (International Renal Interest Society) recommend monitoring renal function in animals with chronic urolithiasis. (7) Research on urease inhibitors (e.g., acetohydroxamic acid) has shown efficacy in experimental models, but they are not commonly used in clinical practice due to side effects.